Key result
Peripheral-ROI CT outperforms volumetric analysis for detecting mild hepatic steatosis with ~0.81 AUC.
Why the study?
The study evaluated semi-automated liver CT attenuation measurement methods to objectively assess MASLD severity while eliminating manual measurement variability.
Does semi-automated CT attenuation measurement using peripheral-ROI or volumetric methods accurately detect hepatic steatosis severity compared to manual measurement in adults suspected of MASLD?
Observational (n=179)
No
Does semi-automated CT attenuation measurement using peripheral-ROI or volumetric methods accurately detect hepatic steatosis severity compared to manual measurement in adults suspected of MASLD?
Effect estimate: AUC 0.809 (95% CI 0.677, 0.941)
Absolute Event Rate: 0.809% vs 0.69%
p-value: p=<0.001
Semi-automated peripheral-ROI CT attenuation measurement provides comparable diagnostic accuracy to manual measurement for mild-to-moderate hepatic steatosis, offering a scalable tool for opportunistic MASLD screening.
Peripheral-ROI CT may aid mild steatosis detection; leaves open replacement of manual methods across severities.
This study aimed to evaluate semi-automated liver CT attenuation measurement methods for assessing metabolic dysfunction-associated steatotic liver disease (MASLD) severity. Adult patients suspected of having MASLD were retrospectively recruited from Zhujiang Hospital between June 2020 and June 2022. Liver segmentation was performed using nnU-Net, with manual refinement performed in 71 of 179 cases (39.7%). Two distinct semi-automated quantification approaches: (1) whole-liver volumetric analysis and (2) peripheral region-of-interest (ROI) measurement, were implemented to objectively assess hepatic steatosis severity while eliminating manual measurement variability. The associations between steatosis level and MRI-PDFF values were analyzed using Spearman’s correlation coefficient. The diagnostic performance of hepatic steatosis severity (mild: MRI-PDFF ≥ 5%; moderate: MRI-PDFF ≥ 14%; severe: MRI-PDFF ≥ 28%) was evaluated through receiver operating characteristic (ROC) curve analysis and compared to manual measurement outcomes. A total of 179 patients were included (mean age, 34.38 years ± 10.67, 96 men), with 150 exhibiting hepatic steatosis (MRI-PDFF ≥ 5%). The peripheral-ROI method outperformed volumetric analysis for detecting hepatic steatosis with MRI-PDFF ≥ 5%, achieving AUCs of 0.809 (95% CI: 0.677, 0.941; P < .001), 0.854 (95% CI: 0.776, 0.931; P < .001), and 0.655 (95% CI: 0.454, 0.856; P < .001) for the ≥ 5%, ≥ 14%, and ≥ 28% thresholds, respectively. Compared with manual measurement, the peripheral-ROI method showed comparable performance at the ≥ 5% and ≥ 14% thresholds but was significantly inferior at the ≥ 28% threshold ( P = .041). The peripheral-ROI measurement technique based on nnU-Net automatic segmentation achieves classification performance comparable to manual measurement for mild-to-moderate steatosis (MRI-PDFF < 28%), while manual measurement remains superior for severe steatosis (MRI-PDFF ≥ 28%). Longitudinal observation suggests its potential for follow-up monitoring in clinical practice, though further studies with larger cohorts are needed.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) conducted an observational in Metabolic dysfunction-associated steatotic liver disease (MASLD) (n=179). Peripheral-ROI CT attenuation measurement vs. Volumetric CT attenuation measurement and manual measurement was evaluated on Diagnostic performance (AUC) for detecting hepatic steatosis (MRI-PDFF ≥ 5%) (AUC 0.809, 95% CI 0.677, 0.941, p=<0.001). The peripheral-ROI CT measurement method achieved an AUC of 0.809 for detecting mild hepatic steatosis, outperforming volumetric analysis and performing comparably to manual measurement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: